Dataset Information

Improved quantification precision of human brain short echo-time (1) H magnetic resonance spectroscopy at high magnetic field: a simulation study.

ABSTRACT: The gain in quantification precision that can be expected in human brain (1) H MRS at very high field remains a matter of debate. Here, we investigate this issue using Monte-Carlo simulations.Simulated human brain-like (1) H spectra were fitted repeatedly with different noise realizations using LCModel at B0 ranging from 1.5T to 11.7T, assuming a linear increase in signal-to-noise ratio with B0 in the time domain, and assuming a linear increase in linewidth with B0 based on experimental measurements. Average quantification precision (Cramér-Rao lower bound) was then determined for each metabolite as a function of B0 .For singlets, Cramér-Rao lower bounds improved (decreased) by a factor of ? B0 as B0 increased, as predicted by theory. For most J-coupled metabolites, Cramér-Rao lower bounds decreased by a factor ranging from B0 to B0 as B0 increased, reflecting additional gains in quantification precision compared to singlets owing to simplification of spectral pattern and reduced overlap.Quantification precision of (1) H magnetic resonance spectroscopy in human brain continues to improve with B0 up to 11.7T although peak signal-to-noise ratio in the frequency domain levels off above 3T. In most cases, the gain in quantification precision is higher for J-coupled metabolites than for singlets.

SUBMITTER: Deelchand DK

PROVIDER: S-EPMC3907456 | biostudies-literature | 2014 Jul

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Improved quantification precision of human brain short echo-time (1) H magnetic resonance spectroscopy at high magnetic field: a simulation study.

Deelchand Dinesh Kumar DK Iltis Isabelle I Henry Pierre-Gilles PG

Magnetic resonance in medicine 20130730 1

<h4>Purpose</h4>The gain in quantification precision that can be expected in human brain (1) H MRS at very high field remains a matter of debate. Here, we investigate this issue using Monte-Carlo simulations.<h4>Methods</h4>Simulated human brain-like (1) H spectra were fitted repeatedly with different noise realizations using LCModel at B0 ranging from 1.5T to 11.7T, assuming a linear increase in signal-to-noise ratio with B0 in the time domain, and assuming a linear increase in linewidth with B ...[more]

PMID: 23900976

Similar Datasets

Project description:BackgroundProton magnetic resonance spectroscopy (1 H-MRS) of the human heart is deemed to be a quantitative method to investigate myocardial metabolite content, but thorough validations of in vivo measurements against invasive techniques are lacking.PurposeTo determine measurement precision and accuracy for quantifications of myocardial total creatine and triglyceride content with localized 1 H-MRS.Study typeTest-retest repeatability and measurement validation study.SubjectsSixteen volunteers and 22 patients scheduled for open-heart aortic valve replacement or septal myectomy.Field strength/sequenceProspectively ECG-triggered respiratory-gated free-breathing single-voxel point-resolved spectroscopy (PRESS) sequence at 3 T.AssessmentMyocardial total creatine and triglyceride content were quantified relative to the total water content by fitting the 1 H-MR spectra. Precision was assessed with measurement repeatability. Accuracy was assessed by validating in vivo 1 H-MRS measurements against biochemical assays in myocardial tissue from the same subjects.Statistical testsIntrasession and intersession repeatability was assessed using Bland-Altman analyses. Agreement between 1 H-MRS measurements and biochemical assay was tested with regression analyses.ResultsThe intersession repeatability coefficient for myocardial total creatine content was 41.8% with a mean value of 0.083% ± 0.020% of the total water signal, and 36.7% for myocardial triglyceride content with a mean value of 0.35% ± 0.13% of the total water signal. Ex vivo myocardial total creatine concentrations in tissue samples correlated with the in vivo myocardial total creatine content measured with 1 H-MRS: n = 22, r = 0.44; P < 0.05. Likewise, ex vivo myocardial triglyceride concentrations correlated with the in vivo myocardial triglyceride content: n = 20, r = 0.50; P < 0.05.Data conclusionWe validated the use of localized 1 H-MRS of the human heart at 3 T for quantitative assessments of in vivo myocardial tissue metabolite content by estimating the measurement precision and accuracy.Level of evidence2 TECHNICAL EFFICACY STAGE: 2.

Project description:The main objective of this study was to utilize high field (7T) in vivo proton magnetic resonance imaging to increase the ability to detect metabolite changes in people with ALS, specifically, to quantify levels of glutamine and glutamine separately. The second objective of this study was to correlate metabolic markers with clinical outcomes of disease progression. 13 ALS participants and 12 age-matched healthy controls (HC) underwent 7 Tesla MRI and MRS. Single voxel MR spectra were acquired from the left precentral gyrus using a very short echo time (TE = 5 ms) STEAM sequence. MRS data was quantified using LCModel and correlated to clinical outcome markers. N-acetylaspartate (NAA) and total NAA (tNA, NAA + NAAG) were decreased by 17% in people with ALS compared to HC (P = 0.004 and P = 0.005, respectively) indicating neuronal injury and/or loss in the precentral gyrus. tNA correlated with disease progression as measured by forced vital capacity (FVC) (P = 0.014; Rρ = 0.66) and tNA/tCr correlated with overall functional decline as measured by worsening of the ALS Functional Rating Scale-Revised (ALSFRS-R) (P = 0.004; Rρ = -0.74). These findings underscore the importance of NAA as a reliable biomarker for neuronal injury and disease progression in ALS. Glutamate (Glu) was 15% decreased in people with ALS compared to HC (P = 0.02) while glutamine (Gln) concentrations were similar between the two groups. Furthermore, the decrease in Glu correlated with the decrease in FVC (P = 0.013; Rρ = 0.66), a clinical marker of disease progression. The decrease in Glu is most likely driven by intracellular Glu loss due to neuronal loss and degeneration. Neither choline containing components (Cho), a marker for cell membrane turnover, nor myo-Inositol (mI), a suspected marker for neuroinflammation, showed significant differences between the two groups. However, mI/tNA was correlated with upper motor neuron burden (P = 0.004, Rρ = 0.74), which may reflect a relative increase of activated microglia around motor neurons. In summary, 7T 1H MRS is a powerful non-invasive imaging technique to study molecular changes related to neuronal injury and/or loss in people with ALS.

Project description:Medulloblastoma (MB) is the most common malignant brain tumor occurring in childhood and rarely found in adult. Based on transcriptome profile MB are currently classified into four major molecular groups reflecting a considerable biological heterogeneity: WNT-activated, SHH-activated, group 3 and group 4. Recently, DNA methylation profiling allowed the identification of additional subgroups within the four major molecular groups associated with different clinic-pathological and molecular features. Isocitrate Dehydrogenase-1 (IDH1) mutations have been described in several tumours, including gliomas, while in MB are exceptionally reported and not routinely investigated. By mean of magnetic resonance spectroscopy (MRS) we unequivocally assessed the presence the oncometabolite D-2-Hydroxyglutarate (2HG), a marker of IDH1 and IDH2 mutation, in a case of adult MB. Immunophenotypical work-up and methylation profiling assigned the diagnosis of MB, subclass SHH-A, and molecular testing revealed the presence of the non-canonical somatic IDH1(p.R132C) mutation and an additional GNAS mutation, also exceptionally described in MB. To our knowledge this is the first reported case of MB harboring both mutations together. Of note, tumour exhibited a heterogeneous phenotype with a tumour component displaying glial differentiation, with robust GFAP expression, and a component with conventional MB features and selective presence of GNAS mutation, suggesting coexistence of two different major tumour clones. These findings draw attention to the need of a deeper genetic characterization of MB in order to get insights into their biology and improve stratification and clinical management of the patients. Moreover, reported data underling the importance of performing MRS for the identification of IDH mutations in non-glial tumours. The use of throughput molecular profiling analysis and advanced medical imaging technology will certainly increase the frequency with which rare tumour entities will be identified. Whether they have any particular therapeutic implications or prognostic relevance requires further investigations.

Dataset Information

Improved quantification precision of human brain short echo-time (1) H magnetic resonance spectroscopy at high magnetic field: a simulation study.

Publications

Improved quantification precision of human brain short echo-time (1) H magnetic resonance spectroscopy at high magnetic field: a simulation study.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets